Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets

NCT01037491 | Unknown

• 1 other identifier: VGH97-10-04
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Clopidogrel causes significantly less peptic ulcer disease (PUD) and ulcer bleeding than low-dose aspirin in general population. However, clopidogrel is not safe enough for gastrointestinal (GI) mucosa in patients who had past history of aspirin-associated ulcer or ulcer bleeding. Aspirin plus proton pump inhibitor (PPI) is superior to clopidogrel alone in preventing recurrent ulcer bleeding in these high risk patients. This study is to compare the ulcer healing rate and ulcer bleeding at 12 weeks in patients with aspirin-associated PUD when they take PPI (rabeprazole 20 mg/day) to treat their PUD and simultaneously take aspirin or clopidogrel for their cardiovascular (CV) prevention. Two hundred patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks. The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks. If rabeprazole plus aspirin in not inferior to rabeprazole plus clopidogrel in the incidence of ulcer healing and ulcer bleeding in the healing phase,PPI plus aspirin rather than PPI plus clopidogrel will be recommended during acute ulcer healing in patients who need antiplatelet therapy for their CV prevention.

Conditions

Gastric Ulcer; Duodenal Ulcer

Keywords

aspirin, clopidogrel, peptic ulcer, proton pump inhibitor, rabeprazole, ulcer bleeding

Outcome Measures

Primary Outcomes (1)

• The primary end point is treatment success (ulcer healing rate).

  3 months

Secondary Outcomes (1)

• The secondary end point is incidence of ulcer bleeding within 12 weeks.

  3 months

Study Arms (2)

aspirin

ACTIVE COMPARATOR

Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.

Drug: rabeprazole plus aspirin versus rabeprazole plus clopidogrel

clopidogrel

ACTIVE COMPARATOR

Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.

Drug: rabeprazole plus aspirin versus rabeprazole plus clopidogrel

Interventions

rabeprazole plus aspirin versus rabeprazole plus clopidogrel DRUG

The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.

aspirin; clopidogrel

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD. PUD in the upper gastrointestinal (UGI) tract is defined as
• \[1\] mucosal break of stomach or duodenum \> 3 mm in diameter; or
• \[2\] more than 10 gastric or duodenal erosions, without malignancy proved by histopathological examination.

You may not qualify if:

• Patients will be excluded if they have PUD with bleeding (ulcer with adherent blood clot, visible vessel, oozing, or spurting) requiring endoscopic hemostasis,
• if they take other antithrombotic or anticoagulants simultaneously, if they have take NSAIDs, selective COX-2 inhibitors, or steroid,
• if they have take misoprostol or histamine receptor-2 antagonist (H2RA),
• if they have bleeding tendency (thrombocytopenia with platelet count \< 80000/mm3 or prolonged pro thrombin time \> 5 seconds),
• if they have anemia (hemoglobin \< 10 g/dL),
• if they have received a surgical intervention due to PUD complication (bleeding, perforation, obstruction) in the past,
• if their age are \> 80 year-old or \< 18 year-old,
• if they have severe cardiovascular, pulmonary, hepatic, or renal disease.

Sponsors & Collaborators

• Taipei Veterans General Hospital, Taiwan: lead

Study Sites (1)

Taipei Veterans General Hospital

Taipei, Taiwan, 11217, Taiwan

RECRUITING

Related Publications (1)

• Luo JC, Huang KW, Leu HB, Chen LC, Hou MC, Li CP, Lu CL, Lin HC, Lee FY, Lee SD. Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. Aliment Pharmacol Ther. 2011 Sep;34(5):519-25. doi: 10.1111/j.1365-2036.2011.04760.x. Epub 2011 Jul 5.

  PMID: 21726257 DERIVED

MeSH Terms

Conditions

Stomach Ulcer; Duodenal Ulcer; Peptic Ulcer

Interventions

Rabeprazole; Clopidogrel

Condition Hierarchy (Ancestors)

Duodenal Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Stomach Diseases

Intervention Hierarchy (Ancestors)

2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Ticlopidine; Thienopyridines; Thiophenes

Central Study Contacts

Jiing-Chyuan Luo, M.D.

CONTACT

886-2-28712121; jcluo@vghtpe.gov.tw

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV

Study Record Dates

• First Submitted: December 21, 2009
• First Posted: December 23, 2009
• Study Start: October 1, 2009
• Primary Completion: December 1, 2010
• Study Completion: December 1, 2010
• Last Updated: June 8, 2010

Record last verified: 2010-06

Locations

TW (1)